Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

Rekombinanter PDCD1 (Spartalizumab Biosimilar) Antikörper

Reaktivität: Human FACS, in vivo Wirt: Maus Monoclonal unconjugated Recombinant Antibody
Produktnummer ABIN7200669
  • Target
    PDCD1 (Spartalizumab Biosimilar)
    Antikörpertyp
    Recombinant Antibody
    Reaktivität
    Human
    Wirt
    Maus
    Klonalität
    Monoklonal
    Applikation
    Flow Cytometry (FACS), In vivo Studies (in vivo)
    Verwendungszweck
    Spartalizumab Biosimilar, Human PD-1 Monoclonal Antibody
    Spezifität
    The in vivo grade spartalizumab biosimilar specifically binds to the programmed cell death protein 1 (PD-1), antagonizing its interaction with its known ligands PD-L1 and PD-L2.
    Produktmerkmale
    Recombinant Humanized IgG4 Monoclonal Antibody.
    Aufreinigung
    Protein A affinity column
    Reinheit
    > 95% by SDS-PAGE under reducing conditions and HPLC.
    Sterilität
    0.2 μm filtered
    Endotoxin-Niveau
    < 1 EU per 1 mg of the protein by the LAL method.
    Immunogen
    The anti-human PD-1 monoclonal antibody spartalizumab biosimilar was produced in mammalian cells.
    Isotyp
    IgG4 kappa
  • Applikationshinweise
    ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by spartalizumab.
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Konzentration
    1 mg/mL
    Buffer
    PBS, pH 7.4, no stabilizers or preservatives.
    Konservierungsmittel
    Without preservative
    Handhabung
    Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
    Lagerung
    -20 °C
    Informationen zur Lagerung
    12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
    Haltbarkeit
    12 months
  • Target
    PDCD1 (Spartalizumab Biosimilar)
    Substanzklasse
    Biosimilar
    Hintergrund
    Spartalizumab Biosimilar uses the same protein sequences as the therapeutic antibody spartalizumab. A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, spartalizumab binds to PD-1 expressed on activated T cells and blocks the interaction with its ligands, programmed cell death 1 ligand 1 (PD-L1, PD-1L1) and PD-1 ligand 2 (PD-L2, PD-1L2). The inhibition of ligand binding prevents PD-1-mediated signaling and results in both T-cell activation and the induction of T-cell-mediated immune responses against tumor cells. PD-1, an immunoglobulin (Ig) superfamily transmembrane protein and inhibitory receptor, negatively regulates T-cell activation.
Sie sind hier:
Kundenservice